PET-based risk stratification for adverse events under [225Ac]Ac-PSMA radioligand therapy. - Widjaja L; Siegmund SC; Gildehaus FJ; Schmidt-Hegemann NS; Pomper MG; Rowe SP; Bundschuh RA; Wenter V; Sheikh GT; Klimek K; Stief CG; Zacherl MJ; et al. (European journal of nuclear medicine and molecular imaging, 2026)